Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-8068 + adebrelimab + cisplatin + gemcitabine
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**SHR-8068 + adebrelimab + cisplatin + gemcitabine** is a four-drug combination therapy. SHR-8068 is an anti-CTLA-4 monoclonal antibody, adebrelimab is an anti-PD-L1 monoclonal antibody, cisplatin is a platinum-based chemotherapeutic agent that crosslinks DNA, and gemcitabine is a nucleoside analog chemotherapeutic that inhibits DNA synthesis. The combination is studied for advanced refractory cancers and is designed to leverage dual immune checkpoint blockade (CTLA-4 and PD-L1) in conjunction with cytotoxic chemotherapy, aiming to enhance anti-tumor immune response and direct cytotoxicity.
- Other names
- SHR-8068SHR8068SHR 8068adebrelimabcisplatingemcitabine
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on SHR-8068 + adebrelimab + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-8068 + adebrelimab + cisplatin + gemcitabine.